What is the best treatment for candidal balanitis in a male diabetic patient taking empagliflozin (Jardiance) without stopping the medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Candidal Balanitis in Diabetic Patients on Empagliflozin

For candidal balanitis in a diabetic male taking empagliflozin, treat with topical clotrimazole 1% cream twice daily for 7 days, or alternatively, a single oral dose of fluconazole 150 mg. Both regimens achieve >90% clinical cure rates and are equally effective 1, 2.

Primary Treatment Options

The IDSA guidelines do not specifically address genital candidiasis in males, but the evidence strongly supports two equivalent first-line approaches:

  • Topical clotrimazole 1% cream: Apply twice daily for 7 days. This achieves 91% symptom resolution and 90% mycological cure at one week 1.

  • Oral fluconazole 150 mg: Single dose. Achieves 92% clinical cure/improvement with 78% mycological eradication, comparable to topical therapy 2.

The oral route is preferred by most patients (12 of 15 patients in one study) who have previously used topical therapy, making fluconazole the more practical choice for adherence 2.

Critical Context: SGLT2 Inhibitor-Associated Risk

The FDA label for Jardiance explicitly warns that empagliflozin increases the risk for genital mycotic infections 3. This is a class effect of SGLT2 inhibitors due to drug-induced glucosuria creating a favorable environment for Candida growth 4, 5.

Important clinical pitfall: Patients may develop recurrent candidal balanitis even with excellent glycemic control (HbA1c 5-5.6) while on SGLT2 inhibitors 5. This occurs because the mechanism is glucosuria-mediated, not hyperglycemia-mediated. Ten patients in one series had normalized HbA1c but continued experiencing recurrent infections due to empagliflozin 5.

Why Not Stop Empagliflozin?

While the FDA label states to "monitor and treat as appropriate" for genital mycotic infections 3, discontinuation is rarely necessary. The evidence shows:

  • Most infections are mild to moderate in severity 4, 6
  • They respond well to standard antifungal treatment 4
  • Discontinuation due to genital infections is rare 4, 6
  • The cardiovascular and renal benefits of empagliflozin typically outweigh the infection risk for morbidity and mortality outcomes

Management Algorithm

  1. Acute treatment: Prescribe either topical clotrimazole for 7 days OR single-dose oral fluconazole 150 mg
  2. Optimize diabetes control: Even though glucosuria is drug-induced, poor glycemic control (HbA1c ≥9%) significantly worsens severity 7
  3. Monitor for recurrence: If infections recur frequently (>3-4 episodes/year), consider:
    • Chronic suppressive fluconazole 100 mg three times weekly (extrapolated from IDSA recommendations for recurrent mucosal candidiasis) 8
    • Re-evaluate risk-benefit of continuing empagliflozin with endocrinology
  4. Watch for complications: If symptoms worsen or spread beyond the glans/foreskin, consider progression to epididymo-orchitis, which can occur with SGLT2 inhibitors and requires urgent evaluation 9

Additional Considerations

Ensure proper hygiene: For uncircumcised men, emphasize gentle retraction and cleaning of the foreskin, as mechanical factors contribute to recurrence.

Rule out other causes: If treatment fails, consider non-candidal etiologies including bacterial infection, lichen sclerosus, psoriasis, or other dermatoses that may require biopsy 10.

Partner treatment: Not routinely necessary for candidal balanitis unless the partner has symptomatic vulvovaginal candidiasis.

The key distinction here is recognizing that SGLT2 inhibitor-associated candidal balanitis is a pharmacologic side effect requiring antimicrobial management, not an indication to stop a medication with proven mortality benefits in diabetic patients. The infection risk is manageable with appropriate antifungal therapy while maintaining the cardiovascular and renal protective effects of empagliflozin.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.